Developing a cancer drug without Big Pharma: this hospital shows it can be done

Unpatentable / “Simple” Cancer Therapies (Vitamin C focus)

• Major subthread on high‑dose IV vitamin C as an adjunct cancer therapy.
• Pro‑side:
  • Cites mechanistic work and clinical data suggesting cytotoxic effects on cancer cells, especially with IV high doses versus ineffective oral dosing.
  • Points to umbrella reviews, RCTs in advanced pancreatic and colorectal cancer, and many case reports indicating longer survival, slower progression, and better quality of life when combined with standard chemo.
  • Argues research is underfunded because vitamin C is not patentable, not because of lack of promise.
• Skeptical side:
  • Labels high‑dose vitamin C as recurrent “quackery.”
  • Notes vitamin C is broadly cytotoxic at high doses, cancers often evolve resistance, and evidence so far shows at best survival extension, not cures.
  • Cites data that some antioxidants worsen cancer; counters that this is about other vitamins, not C.
• Both sides agree: more and better trials would be needed to settle efficacy; safety of vitamin C itself is mostly established.

Cost, Complexity, and Regulation of Trials

• Many comments emphasize that rigorous clinical trials are inherently expensive and logistically hard:
  • Need for ethical design, monitoring, manufacturing quality, liability coverage, and regulatory‑grade documentation.
  • Phase III cancer trials can run into tens or hundreds of millions, with high per‑patient costs and large, complex dossiers.
• Disagreement over how much of this is genuine scientific/ethical necessity versus bureaucracy, CRO markups, and regulatory accretion.

Hospital‑Led Cancer Drug Development

• The discussed hospital‑run phase III trial (TIL therapy) is seen as a notable proof that large, late‑stage oncology trials can be done largely outside Big Pharma, with charity and institutional support.
• Others note it still relies on existing regulatory structures and isn’t a fully “pharma‑free” model.

Pharma Incentives, Doctors, and Systemic Critiques

• One camp argues: effective treatments can’t be ignored for decades because doctors, patients, and researchers are strongly motivated by outcomes and recognition.
• Counter‑camp:
  • Doctors face debt, institutional pressure, and regulatory risk; they rarely drive unproven, non‑commercial ideas.
  • Big‑trial selection is shaped by patents, profit, egos, and academic incentives, not just science.
  • Many potentially useful but unpatentable or off‑label options never get definitive trials.

Cancer Vaccines and Immunotherapy

• Cuba’s CIMAvax and other “cancer vaccines” are discussed as therapeutic vaccines: they induce an immune response against tumor‑related targets (e.g., EGF/EGFR), rather than preventing initial cancer.

Drug Discovery Limits and Reform Ideas

• Several participants highlight:
  • Poor predictive power of animal and preclinical models (especially in neurodegeneration and oncology).
  • ~10% success rate from phase I to approval; much of the total cost comes from failed candidates.
  • Calls for better mechanistic modeling, AI‑assisted prediction, and alternative funding models, but recognition that regulation and patient safety limit “move fast and break things.”

Ethics, Exploitation, and Underground Trials

• Proposals to run cheap trials on underserved populations or via apps draw strong criticism as coercive and scientifically weak.
• Claims that billionaires run private “underground” trials; not substantiated or deeply explored in the thread, but mentioned as a symptom of mistrust in formal systems.

AI and Future Disruption

• Some expect AI to transform drug discovery, forecasting efficacy from preclinical data and reducing failed trials.
• Others caution that biology’s complexity, ethics, and centralized regulation make “Uber‑style” disruption unlikely.

Anecdotes and Fringe Treatments

• The thread contains personal anecdotes (e.g., alternative protocols for Parkinson’s) and direct promotion of specific clinics/protocols.
• These are presented without corroborating data and implicitly treated by others as outside evidence, not as established therapies.